Ophthalmic Suspension Market Aggrandizes Growth at 6.8% Worldwide with Novartis AG, ALLERGAN, Pfizer Inc., Bayer Aga; Asserts MRFR

The suspension in the form of used to treat eye infections and related symptoms are generally termed as ophthalmic suspension. Generally it used in a combination of two such as antibiotics and a corticosteroid for more effective treatment. Various bacterial eye infections such as conjunctivitis are treated by ophthalmic suspension. The Global Ophthalmic Suspension Market is expected to grow at a CAGR of ~6.8% during the forecast period 2018-2023.

Click to Get Sample Report @ https://www.marketresearchfuture.com/sample_request/4350 .

Different suspensions are available in the market to treat eye infections and related symptoms. These together are referred to as ophthalmic suspensions. Generally, these suspensions are used in combination of antibiotics and a corticosteroid which ensures effective treatment. Bacterial eye infections such as conjunctivitis can be effectively treated by the ophthalmic suspensions. Rising prevalence of eye diseases is one of the major driver for the growth of the market, during the forecast period.

Moreover, growing geriatric population susceptible to various eye disorders, and rising number of reported cases of bacterial infections in children boosts the market. According to the World Health Organization in 2014, glaucoma is one of the second major causes of blindness in the world. It was also estimated that the global prevalence of the same will increase, fuelling the market growth. However, side-effects associated by the application of ophthalmic suspension is estimated to restrain the market growth during the projected period.

Global Ophthalmic Suspension Market - Key Players
Some of the key players in this market are:

Novartis AG (Alcon)
ALLERGAN
Pfizer Inc.
Merck & Co. Inc.
Bausch & Lomb Incorporated
Falcon Group
Valeant
Bayer Aga
Genentech Inc.
Global Ophthalmic Suspension Market - Competitive Analysis

Pfizer Inc. is one of the major players of the global ophthalmic suspension market and is headquartered in the U.S. In 2015, the company’s total revenue was about USD 48,851 million and it reached USD 52,824 million in 2016. Such a significant increase in the global sales, enabled the company to invest a huge percentage of their sales into the research and development. In 2016, the company spent 14.9% of its total revenue into the R&D enabling it to improve its product portfolio and launch new product, strengthening its position in the market.

In November 2016, Novartis acquired Selexys Pharmaceuticals Corporation, a company specializing in development of therapeutics in certain hematologic and inflammatory disorders.

In June 2016, Merck, known as MSD outside the United States and Canada, and Afferent Pharmaceuticals announced that the two companies signed an agreement under which Merck acquired the privately held company. Afferent Pharmaceuticals is a leader in the development of therapeutic candidates targeting the P2X3 receptor for the treatment of common, poorly-managed, neurogenic conditions.

Get Discount on Report @ https://www.marketresearchfuture.com/check-discount/4350 .

In February 2015, Valeant Pharmaceuticals International, Inc. and Salix Pharmaceuticals, Ltd. entered into a definitive agreement under which Valeant acquired all of the outstanding common stock of Salix for USD 158.00 per share in cash. The transaction was approved by the Boards of Directors of both companies.

Global Ophthalmic Suspension Market – Intended Audience

Ophthalmic Suspension Manufacturers
Ophthalmic Suspension Suppliers
Research and Development (R&D) Companies
Market Research and Consulting Service Providers
Potential Investors
Global Ophthalmic Suspension Market – Segments

The global ophthalmic suspension market is segmented on the basis of type of content, which is segmented into antibiotic, antifungal, antibacterial, steroids, NSAIDs (non-steroidal anti-inflammatory drugs) and others.

On the basis of applications, it is segmented into bacterial infections, retinal disorders, glaucoma, allergies, diabetic eye disease, and others. Bacterial infection is further conjunctivitis, scleritis, and others. Retinal disorder is further segmented into macular degeneration, branch retinal vein occlusion, central retinal vein occlusion, congenital x-linked retinoschisis, and others.

On the basis of end user, the market is segmented into hospitals, eye clinics, pharmacies, and others.

Some of Major Table of Content for “Ophthalmic Suspension Market Research Report - Global Forecast Till 2023”

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

Continued….

To Know More Enquire @ https://www.marketresearchfuture.com/enquiry/4350 .

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
+1 646 845 9312
Email: salesteam@marketresearchfuture.com

This release was published on openPR.